Literature DB >> 12692237

Replication studies using genotype 1a subgenomic hepatitis C virus replicons.

Baohua Gu1, Adam T Gates, Olaf Isken, Sven-Erik Behrens, Robert T Sarisky.   

Abstract

Recently, cell-based replicon systems for hepatitis C virus (HCV), in which the nonstructural proteins stably replicate subgenomic viral RNA in Huh7 cells, were developed. To date, one limitation of using these replicon systems to advance drug discovery is the inability of other genotypic derivatives, beyond those of two distinct strains of genotype 1b (HCV-N and Con1), to stably replicate in Huh7 cells. In this report, we evaluated a series of replicon genotype 1a-1b chimeras, as well as a complete genotype 1a replicon clone. A subgenomic replicon construct containing only type 1a sequences failed to generate stable colonies in Huh7 cells even after repeated attempts. Furthermore, addition of an NS5A adaptive mutation (S2204I) which enhances type 1b replicon efficiency was insufficient to confer replication to the wild-type 1a replicon. This subgenomic replicon was subsequently found to be inefficiently translated in Huh7 cells compared to a type 1b replicon, and the attenuation of translation mapped to the N-terminal region of NS3. Therefore, to ensure efficient translation and thereby support replication of the 1a genome, the coding sequence for first 75 residues from type 1a were replaced with the type 1b (strain Con 1) NS3 coding sequence. Although nonstructural proteins were expressed at lower levels with this replicon than with type 1b and although the amount of viral RNA was also severalfold lower (150 copies of positive-strand RNA per cell), the replicon stably replicated in Huh7 cells. Notwithstanding this difference, the ratio of positive- to negative-strand RNA of 26 was similar to that found with the type 1b replicon. Similar results were found for a 1b replicon expressing the type 1a RNA-dependent RNA polymerase. These 1a hybrid replicons maintained sensitivity to alpha interferon (IFN-alpha), albeit with an eightfold-higher 50% inhibitory concentration than type 1b replicons. Evidence is provided herein to confirm that this differential response to IFN-alpha may be attributed directly to the type 1a polymerase.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12692237      PMCID: PMC153987          DOI: 10.1128/jvi.77.9.5352-5359.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  17 in total

Review 1.  Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome.

Authors:  H J Alter; L B Seeff
Journal:  Semin Liver Dis       Date:  2000       Impact factor: 6.115

2.  Effect of alpha interferon on the hepatitis C virus replicon.

Authors:  J T Guo; V V Bichko; C Seeger
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

3.  Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells.

Authors:  Masanori Ikeda; MinKyung Yi; Kui Li; Stanley M Lemon
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

4.  Development of a strand-specific RT-PCR based assay to detect the replicative form of hepatitis C virus RNA.

Authors:  J K Craggs; J K Ball; B J Thomson; W L Irving; A M Grabowska
Journal:  J Virol Methods       Date:  2001-05       Impact factor: 2.014

5.  Subgenomic replicon derived from a cell line infected with the hepatitis C virus.

Authors:  Hiroe Kishine; Kazuo Sugiyama; Makoto Hijikata; Nobuyuki Kato; Hitoshi Takahashi; Takeshi Noshi; Yasunori Nio; Masahiro Hosaka; Yusuke Miyanari; Kunitada Shimotohno
Journal:  Biochem Biophys Res Commun       Date:  2002-05-10       Impact factor: 3.575

6.  A novel sequence found at the 3' terminus of hepatitis C virus genome.

Authors:  T Tanaka; N Kato; M J Cho; K Shimotohno
Journal:  Biochem Biophys Res Commun       Date:  1995-10-13       Impact factor: 3.575

7.  An amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A.

Authors:  Volker Brass; Elke Bieck; Roland Montserret; Benno Wölk; Jan Albert Hellings; Hubert E Blum; François Penin; Darius Moradpour
Journal:  J Biol Chem       Date:  2001-12-14       Impact factor: 5.157

8.  Mutations in hepatitis C virus RNAs conferring cell culture adaptation.

Authors:  V Lohmann; F Körner; A Dobierzewska; R Bartenschlager
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

9.  Efficient initiation of HCV RNA replication in cell culture.

Authors:  K J Blight; A A Kolykhalov; C M Rice
Journal:  Science       Date:  2000-12-08       Impact factor: 47.728

10.  Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.

Authors:  Dashyant Dhanak; Kevin J Duffy; Victor K Johnston; Juili Lin-Goerke; Michael Darcy; Antony N Shaw; Baohua Gu; Carol Silverman; Adam T Gates; Michael R Nonnemacher; David L Earnshaw; David J Casper; Arun Kaura; Audrey Baker; Cathy Greenwood; Lester L Gutshall; Derrick Maley; Alfred DelVecchio; Ricardo Macarron; Glenn A Hofmann; Zaid Alnoah; Hung-Yuan Cheng; George Chan; Sanjay Khandekar; Richard M Keenan; Robert T Sarisky
Journal:  J Biol Chem       Date:  2002-08-06       Impact factor: 5.157

View more
  18 in total

1.  The nonstructural protein 3 protease/helicase requires an intact protease domain to unwind duplex RNA efficiently.

Authors:  David N Frick; Ryan S Rypma; Angela M I Lam; Baohua Gu
Journal:  J Biol Chem       Date:  2003-10-29       Impact factor: 5.157

2.  Identification of a naturally occurring recombinant genotype 2/6 hepatitis C virus.

Authors:  Suwanna Noppornpanth; Truong Xuan Lien; Yong Poovorawan; Saskia L Smits; Albert D M E Osterhaus; Bart L Haagmans
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

3.  Hepatitis B and hepatitis C virus replication upregulates serine protease inhibitor Kazal, resulting in cellular resistance to serine protease-dependent apoptosis.

Authors:  Jason Lamontagne; Mark Pinkerton; Timothy M Block; Xuanyong Lu
Journal:  J Virol       Date:  2009-10-28       Impact factor: 5.103

4.  Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon.

Authors:  Takanobu Kato; Tomoko Date; Michiko Miyamoto; Zijiang Zhao; Masashi Mizokami; Takaji Wakita
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay.

Authors:  Donald R O'Boyle; Peter T Nower; Julie A Lemm; Lourdes Valera; Jin-Hua Sun; Karen Rigat; Richard Colonno; Min Gao
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

6.  Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells.

Authors:  MinKyung Yi; Stanley M Lemon
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

7.  Hepatitis C virus subgenomic replicons in the human embryonic kidney 293 cell line.

Authors:  Samir Ali; Charles Pellerin; Daniel Lamarre; George Kukolj
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

8.  Genetic interactions between hepatitis C virus replicons.

Authors:  Matthew J Evans; Charles M Rice; Stephen P Goff
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

9.  alpha-Galactosylceramide and novel synthetic glycolipids directly induce the innate host defense pathway and have direct activity against hepatitis B and C viruses.

Authors:  Anand S Mehta; Baohua Gu; Bertha Conyers; Serguey Ouzounov; Lijuan Wang; Robert M Moriarty; Raymond A Dwek; Timothy M Block
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

10.  Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay.

Authors:  Steven W Ludmerer; Donald J Graham; Evelyn Boots; Edward M Murray; Amy Simcoe; Eric J Markel; Jay A Grobler; Osvaldo A Flores; David B Olsen; Daria J Hazuda; Robert L LaFemina
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.